HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Investigator: Mahwash Kassi, MD

Study Coordinator: Jan-Michael Ragunton

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT04153149

Phone: 713.441.9837

Protocol Number: PRO00027010


This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.
More to Explore